A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This randomized, open-label study will compare the efficacy and safety of MabThera/Rituxan (rituximab) alone, and in combination with Roferon-A (interferon alfa-2a) in patients with follicular or other CD20+ low-grade lymphoma. Patients will be randomized to receive either MabThera/Rituxan 375 mg/m2 intravenously weekly for 4 weeks or Roferon-A 3 MIU/day subcutaneously in Week 1 followed by 4.5 MIU/day sc in Weeks 2-5 plus MabThera/Rituxan 375 mg/m2 weekly iv in Weeks 3-6. Patients who have a response will receive an additional cycle of treatment. The anticipated time on study treatment is up to 6 months.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Collaborator: Nordic Lymphoma Group
• Treatments: Interferon alpha-2; Interferon-alpha; Interferons; Rituximab

Criteria

Inclusion Criteria:

• Adult patients >18 years of age

• CD20+ low-grade (indolent) lymphoma of follicular and marginal zone type, small lymphocytic lymphoma without a B-CLL phenotype, or indolent lymphoma not otherwise specified

• Stage II (with bulky disease), III, or IV lymphoma

• No previous chemotherapy or a maximum of 6 months chlorambucil or cyclophosphamide

• Indication for treatment: symptomatic enlarged lymph nodes, spleen or other lymphoma manifestations, progression >6 months of lymphadenopathy or splenomegaly, anemia or thrombocytopenia or decreased hemoglobin or platelets due to lymphoma, general symptoms (weight loss, night sweats or fever)

• WHO performance status 0-2

Exclusion Criteria:

• Prior treatment with rituximab or an interferon

• B-CLL, mantle cell lymphoma, lymphoplasmacytic lymphoma (Waldenstroem's disease), or central nervous system lymphoma

• Indolent lymphoma transformed into aggressive lymphoma

• Indolent lymphoma with bulky tumor requiring urgent therapy

• Prior malignancies, except non-melanoma skin tumors, in situ cervical cancer, or curative surgery >5 years ago

• Positive for HIV infection

• Uncontrolled asthma or allergy requiring corticosteroids